ATLANTA - Crawford & Company (NYSE:CRD-A and NYSE:CRD-B) announced Monday that its board of directors has appointed W. Bruce Swain, Jr. as president and chief executive officer, effective immediately, according to a press release statement.
Swain had served as interim president and CEO since January 1, 2026. He will continue as a member of Crawford’s executive leadership team and board of directors.
Swain has spent more than 30 years at Crawford, including 19 years as chief financial officer. Jesse Crawford, Jr., non-executive board chair, said the board has confidence in Swain’s ability to lead the company. Under recent leadership, Crawford has maintained solid fundamentals with a market capitalization of $31.7 billion and revenue of $7.07 billion over the last twelve months.
The company also announced that Jesse Crawford, Sr., a board member since 1986 and former board chair, will not stand for reelection at the 2026 Annual Shareholder Meeting scheduled for May 14. The board will appoint Crawford, Sr. as an honorary board member and confer the title of emeritus officer, effective at the conclusion of the meeting.
Crawford, Sr. represents the second generation of the Crawford family’s leadership as the son of founder Jim Crawford. He has served the company for 40 years and remains the majority shareholder.
Crawford & Company is a global provider of claims management and outsourcing solutions to insurance companies and self-insured entities, serving clients in more than 70 countries. The company’s two classes of stock are substantially identical except for voting rights on Class B Common Stock (CRD-B) and protections for Class A Common Stock (CRD-A).
In other recent news, Agilent Technologies Inc. announced the launch of Agilent Advanced Therapeutics, a new unified business unit combining its contract development and manufacturing operations in Canada and the United States. This new division integrates BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado, offering a range of services including oligonucleotide production and cell line development. Agilent also revealed plans to acquire Biocare Medical for approximately $950 million in cash, a move expected to enhance its position in immunohistochemistry. The acquisition, which is subject to regulatory approvals, is anticipated to close by Agilent’s fiscal fourth quarter of 2026. BofA Securities reiterated its Neutral rating and $150.00 price target for Agilent following this acquisition announcement. Additionally, Agilent’s Vice President, Corporate Controller, and Principal Accounting Officer, Rodney Gonsalves, has announced his intention to retire in January 2027. The company emphasized that his retirement is not due to any disagreements over its accounting practices or financial statements. Meanwhile, Crawford & Company announced a partnership with Helixco to enhance its Contractor Connection’s commercial repair operations with real-time documentation technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.